MedTrace Logo

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00060099 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients with cervical intraepithelial neoplasia.

PURPOSE: This randomized phase II trial is studying how well SGN-00101 works in preventing cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.

Conditions

  • Precancerous Condition

Interventions

BIOLOGICAL

HspE7

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Dana-Farber/Brigham and Women's Cancer Center

    lead OTHER

Principal Investigators

  • Kristin A. Keefe, MD · Dana-Farber/Brigham and Women's Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00060099 on ClinicalTrials.gov